A Study to Assess the Safety of Myozyme® and of Aldurazyme® in Male and Female Participants of any Age Group With Pompe Disease or With Mucopolysaccharidosis Type I (MPS I) in a Home-Care Setting

study id #: NCT05073783

condition: Pompe Disease, Mucopolysaccharidosis Type I (MPS I)

status: Not yet recruiting

purpose:

Primary Objective:

To obtain data pertaining to the safety and tolerability of alglucosidase alfa and laronidase treatments administered in a home-care infusion setting.

Secondary Objectives:

To evaluate personal satisfaction of both cohorts of patients treated in a home-care infusion setting.
To evaluate the infusion compliance in both cohorts of patients treated in a home-care infusion setting.

results: https://clinicaltrials.gov/ct2/show/results/NCT05073783

last updated: February 26, 2022

start date: October 14, 2021

estimated completion: January 2, 2024

last updated: October 11, 2021

size / enrollment: 60

study description: Prospective observation duration for each patient: at least 12 months (from enrollment)

primary outcomes:

• Number of participants with treatment-emergent adverse events (TEAEs)
  Treatment emergent adverse events (TEAEs) are defined as any event which are not present prior to the initiation of the Enzyme replacement therapy (ERT) administration in homecare setting or any event already present that worsens in either intensity or frequency following initiation of ERT administration in home-care setting.
• For at least 12 months starting from enrollment (day 0)
  Number of participants with treatment-emergent adverse events (TEAEs) for each class of severity
  TEAEs are defined as any event which are not present prior to the initiation of the ERT administration in homecare setting or any event already present that worsens in either intensity or frequency following initiation of ERT administration in home-care setting. An adverse event grading scale of mild, moderate and severe is used for grading of adverse event severity.
• For at least 12 months starting from enrollment (day 0)
  Number of participants with serious treatment-emergent adverse events (TEAEs)
  A serious adverse event (SAE) is any untoward medical occurrence that at any dose: 1) results in death or 2) is life-threatening or 3) requires inpatient hospitalization or prolongation of existing hospitalization or 4) results in persistent or significant disability/incapacity or 5) is a congenital anomaly/birth defect or 6) is a medically important event.
• For at least 12 months starting from enrollment (day 0)
  Number of participants with treatment-emergent adverse events (TEAEs) related to alglucosidase or laronidase
  TEAEs are defined as any event which are not present prior to the initiation of the ERT administration in homecare setting or any event already present that worsens in either intensity or frequency following initiation of ERT administration in home-care setting. A TEAE is defined as treatment-related if it has a reasonable possibility that the event is related to alglucosidase or laronidase.
• For at least 12 months starting from enrollment (day 0)
  Number of participants with infusion associated reactions (IARs)
  IARs are defined as AEs that occur during either the infusion or the observation period following the infusion which are deemed to be related or possibly related to Myozyme® and Aldurazyme®. At the discretion of the Investigator, AEs occurring after completion of the post-infusion observation period that are assessed as related may also be considered IARs.
• For at least 12 months starting from enrollment (day 0)
  Number of participants with concomitant medications for each Anatomical Therapeutic Chemical (ATC) classification systems
  Participants will be asked about their use of concomitant medication at enrollment.
• At enrollment (day 0)
  Number of participants with change in the use of concomitant medications in case of non-tolerated infusion
  Participants will be asked about their perception regarding any additional medications or treatments or any changes in regimen or dosages compared to their baseline (day 0) state. Any change in the therapy (increased therapy, decrease therapy, no change in therapy) during the study will be reported.
• For at least 12 months starting from enrollment (day 0)
  

secondary outcomes:

• Patient satisfaction
  For at least 12 months starting from enrollment (day 0)
• Patient compliance
  For at least 12 months starting from enrollment (day 0)

inclusion criteria:

Inclusion Criteria:

Signed, informed consent obtained prior to being enrolled into the study and prior to starting any data collection. Consent of a legally authorized guardian is required for legally minor patients as defined by local regulation. If the patient is legally minor, signed written consent shall be obtained from parent(s)/legal guardian and assent obtained from the patient, if applicable.
Pompe disease patients with confirmed acid alpha-glucosidase (GAA) enzyme deficiency treated with Myozyme® in home infusion setting according to authorized clinical practice and the approved risk management plan document (Cohort A) or
MPS I patients with confirmed deficiency of the lysosomal enzyme, alpha-L-iduronidase treated with Aldurazyme® in home infusion setting according to authorized clinical practice and the approved risk management plan document (Cohort B).

exclusion criteria: Criteria:

Participation in another clinical trial with any investigational agent within the 12 weeks preceding enrolment.
Any condition (e.g. medical concern) which, in the opinion of the Investigator, would make the participant unsuitable for the study.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

sponsor: Sanofi

contacts: Trial Transparency Email Recommended (Toll Free For US & Canada), 800-633-1610, Contact-US@sanofi.com

investigators: Clinical Sciences & Operations,Sanofi

trial center locations: